Melinta Therapeutics Announces Appointment of Kristen Allgor as Chief Human Resources Officer

MORRISTOWN, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) — Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced the appointment of Kristen Allgor as Chief Human Resources Officer, effective today.

In August of this year, Christine Ann Miller, a global pharmaceutical veteran, joined Melinta as President and Chief Executive Officer and member of the board. Under Ms. Miller’s leadership, Melinta expects to build upon its existing platform and enhance its world-class antibiotics portfolio with additional products that address therapeutic areas of critical need.

“As we reimagine Melinta’s future, developing a high-performing team culture is essential to realizing our full potential and achieving sustainable growth,” said Ms. Miller. “With Kristen’s proven track record of leading global pharmaceutical organizations through change and building high-performing teams, I’m confident she will be a strong catalyst for helping to lead Melinta through this positive transformation.”

Ms. Allgor is a seasoned human resources executive who joins Melinta from Allergan where she served as Vice President of Human Resources for the past seven years.

At Allergan, she held various roles including business partner to the commercial, finance and technology teams. In this capacity, she led teams through multiple mergers and acquisitions and implemented a global compensation platform for the company.

Prior to Allergan, Ms. Allgor held executive human resources roles at Bausch Health, Pfizer, Virgin Mobile and PepsiCo. In these roles, she focused on implementing best-in-class compensation and benefit programs.

“I am thrilled to join Melinta at this pivotal moment,” said Ms. Allgor. “It’s energizing to be a part of a team so committed to delivering life-saving therapeutics as well as cultivating and valuing the people who will drive our growth. I’m very excited to work with Christine and the rest of the Melinta team as we reimagine our future.”

About Melinta Therapeutics

Melinta Therapeutics, LLC is the largest pure-play antibiotics company, dedicated to providing innovative therapies to people impacted by acute and  life-threatening illnesses. It currently markets four antibiotics: Baxdela® (delafloxacin), Vabomere® (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. This portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.

Contact Information

Susan Blum
(312) 767-0296
info@melinta.com

READ FULL TEXT

Michael N. Dudley, Pharm.D.

President and Chief Executive Officer
Qpex Biopharma, Inc.

Dr. Dudley has over 30 years of experience in antiinfective drug research, development, and commercialization. In 2018, he co-founded Qpex Biopharma which raised $33M in Series A financing and acquired the preclinical infectious disease programs from The Medicines Company. He has overseen the development and regulatory approval of 3 antibiotics, most recently a beta-lactamase inhibitor combination product from a new chemical class (vaborbactam) discovered in the company laboratories. The antibiotic product Vabomere™ advanced from discovery to FDA approval in 2017 in less than 8 years. He lead the negotiation for multiple contracts from public-private partnerships (e.g., BARDA of the US Government; Innovative Medicines Initiative for the EU) for a combined total of over $190 million funding to advance antimicrobial agents in development in the US and Europe. Prior to co-founding Qpex, he was Chief Scientific Officer and co-founder of Rempex Pharmaceuticals that was acquired by the Medicines Company (MDCO) in 2013, where he remained as the co-leader of the Infectious Disease Business Unit of MDCO. Prior to Rempex, he held VP/SVP/CSO positions of increasing responsibility at the biotech companies Mpex Pharmaceuticals (acquired by Aptalis in 2011), Diversa Corporation, and Microcide Pharmaceuticals. Prior to his career in pharmaceutical industry, he held full-time academic appointments that included Professor of Pharmacy and Chairman of the Department of Pharmacy Practice at the University of Rhode Island College of Pharmacy (URI), and Adjunct Professor of Medicine, Brown University School of Medicine at Roger Williams Medical Center in Providence, RI. As an academic researcher, he conducted preclinical and clinical research in antibacterial, antifungal, and antiviral agents, including pioneering work on PK-PD approaches for several classes of antiinfectives. Dr. Dudley has published over 130 scientific papers and book chapters describing the evaluation and clinical use of antiinfective agents and treatment of infectious diseases. He has served as an invited speaker at several FDA and EMA workshops, international meetings on infectious diseases, and advisor to several companies. He has served as an Editor for the journal Antimicrobial Agents and Chemotherapy and numerous other editorial and advisory boards. He completed undergraduate work at Pepperdine University and his Doctor of Pharmacy (PharmD) from the University of California San Francisco (UCSF), completed at residency at UCSF, and a fellowship in infectious diseases at Hartford Hospital.

Melinta Therapeutics Announces Appointment of Kristen Allgor as Chief Human Resources Officer

About Melinta Therapeutics

Contact Information

René Russo, PharmD, BCPS

René Russo, PharmD, BCPS

Roger J. Pomerantz, M.D., F.A.C.P.

Christine Ann Miller

Graham G. Lumsden

Marco Taglietti, M.D.

Ankit Mahadevia

Jeffrey Stein, Ph.D.

Evan Loh, M.D.

Michael Dunne, M.D

Ciara Kennedy, Ph.D.

Ted Schroeder

Kevin Finney

Manos Perros, Ph.D.

David Roblin

Stephen Conafay

Christopher J. Burns, Ph.D.

Michael N. Dudley, Pharm.D.

Ramani Varanasi

Corey Fishman

Felix Faupel

Adrian Nivoliez